Durable HIV treatment benefit despite low-level viremia: Reassessing definitions of success or failure

JAMA

Volumn 286, Issue 2, 2001, Pages 224-226

  Deeks, S G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

CELLULAR IMMUNITY; EDITORIAL; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT FAILURE; VIREMIA; VIRUS REPLICATION;

EID: 0034946066     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.286.2.224     Document Type: Editorial

References (16)

1. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
2. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
3. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/mL receiving combination therapy
4. Prevalence and predictive value of intermittent viremia with combination HIV therapy
5. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy
6. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
7. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
8. Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy
9. Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups
10. Antiretroviral resistance during successful therapy of HIV type 1 infection
11. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
12. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
13. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo
14. Vigorous HIV- 1-specific CD4 T cell responses associated with control of viremia
15. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy